When Novo Nordisk exploded onto the global scene with Ozempic and Wegovy, the world saw a new miracle drug emerge—one that promised to melt fat, suppress hunger, and upend the $4 trillion global health industry. But beneath the headlines and skyrocketing stock prices, the illusion of pharmaceutical dominance was quietly beginning to crack.

According to the American Medical Association, over 70% of patients now prefer virtual visits for non-emergency care. That trend is only accelerating with the emergence of sleek, Silicon Valley-inspired platforms offering care at the tap of a screen.